Belite Bio (BLTE) Liabilities and Shareholders Equity (2021 - 2026)

Belite Bio's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $811.3 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 394.07% year-over-year to $811.3 million; the TTM figure through Mar 2026 stood at $2.0 billion (up 268.81% YoY), while the FY2025 annual figure was $780.6 million, up 413.08% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $811.3 million, up from $780.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $811.3 million in Q1 2026, with the low at $39.8 million in Q1 2023.
• The 5-year median for Liabilities and Shareholders Equity is $117.1 million (2024), against an average of $212.8 million.
• Peak annual rise in Liabilities and Shareholders Equity reached 413.08% in 2025, while the deepest fall reached 32.07% in 2025.
• Belite Bio's Liabilities and Shareholders Equity stood at $44.3 million in 2022, then jumped by 113.77% to $94.6 million in 2023, then soared by 60.74% to $152.1 million in 2024, then surged by 413.08% to $780.6 million in 2025, then rose by 3.94% to $811.3 million in 2026.
• Business Quant data shows BLTE's Liabilities and Shareholders Equity at $811.3 million in Q1 2026, $780.6 million in Q4 2025, and $282.4 million in Q3 2025.